Regulatory Role of ILC2 in Acute Lung Injury in Sepsis

严重脓毒症并发多器官功能障碍综合征(MODS)是导致 重症监护室。急性肺损伤(ALI)是多器官功能障碍综合征(MODS)的重要组成部分，常常是导致死亡的直接原因。 尽管如此，ALI的有效治疗靶点仍然很少。我们的长期目标是确定 脓毒症促进ALI的机制，从而潜在地确定预防的新靶点 干预。先天淋巴样细胞(ILCs)是淋巴系中的新成员，在人类免疫系统中发挥着重要作用。 宿主对炎症、感染和组织损伤的先天免疫反应。国际劳工公约由三个部分组成 子组、ILC1、ILC2和ILC3。ILC2是人类和小鼠肺中主要的ILC亚型，并且 在维持呼吸道屏障完整性和肺组织动态平衡方面发挥重要作用。然而，它的作用是 ILC2在脓毒症诱导的ALI中的作用尚不清楚。本研究项目旨在了解细胞的调节作用 ILC2在ALI的发展和进展中的作用以及ILC2动员、迁移、 在脓毒症中通过三个特定的目标(SA)在肺内扩张：SA1。确定ILC2在 脓毒症后ALI的进展；SA2确定骨髓动员ILC2的机制 和SA3，以确定ILC2在脓毒症中肺内扩张的机制。 败血症。这项研究的结果将为脓毒症中ALI的潜在新疗法提供必要的基础。 通过调节ILC2的迁移、扩展和功能。

Severe sepsis complicated with multiple organ dysfunction syndrome (MODS) is a leading cause of death in ICU. Acute lung injury (ALI) is an important component of MODS and often serves as a direct cause of death. Nonetheless, few effective therapeutic targets for ALI have been identified. Our long-term goal is to determine the mechanisms by which sepsis promote ALI, thereby potentially identifying novel targets for prophylactic intervention. Innate lymphoid cells (ILCs), a new member of the lymphoid population, play a central role in innate immunity of host response to inflammation, infection, and tissue damage. ILCs are composed of three subgroups, ILC1, ILC2, and ILC3. ILC2 are a main ILC subtype in the lungs in both human and mouse, and play an important role in maintaining airway barrier integrity and lung tissue homeostasis. However, the role of ILC2 in sepsis-induced ALI remains unclear. This research project aims to understand the regulatory role of ILC2 in the development and progression of ALI and the mechanism underlying ILC2 mobilization, migration, and expansion in the lung in sepsis through three Specific Aims (SA): SA1. To determine the role of ILC2 in the progression of ALI following sepsis; SA2 To determine the mechanism underlying ILC2 mobilization from BM and migration into the lung in sepsis; and SA3 To determine the mechanism of ILC2 expansion in the lung in sepsis. The results of the study will serve as essential foundation for potential novel treatment of ALI in sepsis by regulating ILC2 migration, expansion, and function.